Working… Menu
Trial record 81 of 332 for:    DONEPEZIL

Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00987220
Recruitment Status : Completed
First Posted : September 30, 2009
Last Update Posted : February 14, 2011
Information provided by:

Brief Summary:
It is hypothesized that the acetylcholinesterase inhibitor, donepezil, will increase acute cerebrospinal fluid (CSF) actylcholine levels in healthy volunteers following a 5mg single dose oral administration.

Condition or disease Intervention/treatment
Alzheimer's Disease Dementia Drug: Placebo Drug: donepezil (Aricept)

Detailed Description:
Sampling method based upon estimates of intra-subject biomarker variability.

Layout table for study information
Study Type : Observational
Actual Enrollment : 12 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: A Methodology Study To Evaluate Cerebrospinal Fluid Acetylcholine Following A Single Dose Administration Of Donepezil In Healthy Subjects
Study Start Date : October 2009
Actual Primary Completion Date : February 2010
Actual Study Completion Date : February 2010

Group/Cohort Intervention/treatment
Placebo Drug: Placebo

donepezil (Aricept) Drug: donepezil (Aricept)
5mg oral
Other Name: Aricept

Primary Outcome Measures :
  1. Mean post-dose vs predose change in CSF acetycholine levels in donepezil compared to placebo control group. [ Time Frame: 6 hrs ]

Secondary Outcome Measures :
  1. Mean post-dose vs predose change in CSF histamine metabolites, sAPPalpha and inflammatory endpoints [ Time Frame: 6hrs ]

Biospecimen Retention:   Samples With DNA
DNA, plasma, CSF

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Young (18-55) male and female healthy volunteers.

Inclusion Criteria:

  • Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
  • Body Mass Index (BMI) of approximately 18 to 33 kg/m2; and a total body weight >50 kg (110 lbs).
  • Subject has the ability to understand the requirements of the study, provide written informed consent, and abide by the requirements of the study.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • History of febrile illness within 5 days prior to the first study period.
  • History of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
  • A positive urine drug screen at screening.
  • Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
  • Use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first study period. As an exception, analgesics, caffeine, and non-pharmacological methods may be used on the discretion of the investigator to manage symptoms related to the lumbar catheterization. Aspirin, aspirin containing products, and non-steroidal anti-inflammatory agents that affect platelet function should not be used. Other exceptions may be granted by a qualified member of Pfizer study management.
  • Treatment with an investigational drug within 30 days preceding the first study period.
  • Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of non-hormonal contraception (as will be outlined in the protocol) from at least 14 days prior to enrollment in the study until completion of the study.
  • Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.
  • Subjects with papilledema on exam at screening or on Day 0.
  • Subject has any laboratory values outside the normal ranges on screening or on Day 0 which are deemed clinically significant by the investigator. Coagulation indices, including PT/aPTT, and platelet count must be normal.
  • Subjects with lower spinal malformations, local infection, or other abnormalities that would exclude lumbar puncture (LP).
  • Subjects who are unwilling or unable to comply with the Lifestyle guidelines presented in the protocol.
  • Other severe acute or chronic medical or psychiatric condition/status or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results, and in the judgment of the investigator, would make the subject inappropriate for entry into this trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00987220

Layout table for location information
United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00987220     History of Changes
Other Study ID Numbers: A9001428
First Posted: September 30, 2009    Key Record Dates
Last Update Posted: February 14, 2011
Last Verified: February 2011
Keywords provided by Pfizer:
CSF Biomarkers Acetylcholine
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents
Vasodilator Agents
Cholinergic Agonists